TrialTargeted oncology2025

Amivantamab-Chemotherapy in Non-Small Cell Lung Cancer with EGFR Exon 20 Insertions: Impact of Treatment Crossover and Other Endpoints from the Phase III PAPILLON Study.

Rachel E Sanborn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.